Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector
| Autor: | Lyudmila Romanyukha, Kevin P. Hieber, Tzu Cheg Kao, Raymond Toles, K. Sree Kumar, Shilpa Kulkarni, Martin Hauer-Jensen, Sanchita P. Ghosh |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Blood Platelets
Male Antioxidant Neutrophils medicine.medical_treatment Radiation-Protective Agents Pharmacology Antioxidants Ionizing radiation Mice chemistry.chemical_compound Leukocytes medicine Animals Vitamin E Radiology Nuclear Medicine and imaging Chromans gamma-Tocotrienol Dose-Response Relationship Drug Radiological and Ultrasound Technology Chemistry Anti oxidant medicine.disease Pancytopenia Regimen Immunology |
| Zdroj: | International Journal of Radiation Biology. 85:598-606 |
| ISSN: | 1362-3095 0955-3002 |
| Popis: | To assess the radioprotective potential of gamma-tocotrienol.To optimise its dose and time regimen, gamma-tocotrienol (GT3) was injected subcutaneously (SC) at different doses into male CD2F1 mice [LD(50/30) (lethal radiation dose that results in the mortality of 50% mice in 30 days) radiation dose of 8.6 Gy with vehicle]. The mice were given 10.5, 11 and 11.5 Gy cobalt-60 radiation, and 30-day survival-protection was determined. Time optimisation was done by SC administration of GT3 at different intervals before irradiation. Dose reduction factor (DRF) was determined by probit analysis using mortality as the end point at six radiation doses. Protection from radiation induced pancytopenia was determined by enumerating peripheral blood cells from mice given GT3 and irradiated at 7 Gy.At an optimal dose of 200 mg/kg given SC 24 h before irradiation, GT3 had a DRF of 1.29. GT3 accelerated the recovery of total white blood cells, neutrophils, monocytes, platelets, and reticulocytes in irradiated mice, compared to vehicle-injected, irradiated controls.GT3 is a radioprotectant having a higher DRF than any other tocols. The protection it provides close to the gastro-intestinal range indicate that GT3 can be considered as an ideal radioprotectant meriting further drug development stages for the ultimate use in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |